Cavan Images One niche area of biotech that I've followed closely over the past several years has been the treatment and pipeline for transthyretin amyloidosis (ATTR). ATTR is a rare genetic disease where a mutation in the TTR gene causes the liver to produce a misfolded protein called transthyretin, which can build up in the body resulting in polyneuropathy and cardiomyopathy. This progressive disease is often diagnosed later in life only after patients start to experience a high disease burden, which incl ...